A Collaboration Between Pfizer and SCLC
SCLC and the Pfizer Independent Grants for Learning & Change (IGLC) (formerly Medical Education Group/MEG), collaborated to award over $4.5 million in grants focused on smoking cessation to 39 organizations nationwide. The grants were divided into three categories (*see below).
A group of expert reviewers and the SCLC volunteered their assistance to this grants program and received no financial remuneration from Pfizer. SCLC is a national program office of the Robert Wood Johnson Foundation and also receives significant support from Legacy. Grant funding for the 39 awardees has been provided entirely by Pfizer.
Announcements
For those grantees working on a one year project, you will be receiving a link to the Mid-point Progress Report, from your technical assistance contact at SCLC. You will have 30 days to complete this survey. If you have any questions, please contact us.
Contact Lists
==============================================================
*Category 1 (17 grantees)
Grants for existing smoking cessation training initiatives. Eligible organizations applied if they have a prior or ongoing project that addresses healthcare provider needs as it relates to improving clinical practice so that it leads to increased smoking cessation quit rates. Projects had a proven track record of success with their educational methods and approach. Documentation was provided that the initiative has achieved success in the past and how additional funding can expand or improve the effort.
*Category 2 (10 grantees)
Grants to individual hospitals or hospital networks for education and quality improvement programs that include implementation of and goals around the achievement of updated Joint Commission smoking cessation performance measures, http://www.jointcommission.org/assets/1/6/Tobacco_Treatment_Measures_List.doc.pdf.
*Category 3 (12 grantees)
Grants in support of state-wide tobacco use reduction projects that include a healthcare provider training component related to smoking cessation. Special emphasis given to states that address high-risk populations with co-morbid conditions, such as smokers with mental health issues and/or substance abuse disorders.
For information about IGLC, visit www.pfizer.com/independentgrants